Go Pro
→ ALERT: Drop these 5 stocks before the market opens tomorrow! (From Weiss Ratings) (Ad)tc pixel Free RCKTW Stock Alerts

Rocket Pharmaceuticals (RCKTW) Competitors

Rocket Pharmaceuticals logo
$0.0060 0.00 (-13.04%)
As of 03:59 PM Eastern
This is a fair market value price provided by Massive. Learn more.
Compare

RCKTW vs. AIMDW, ALVOW, ARAV, ACABW, and BFRIW

Should you buy Rocket Pharmaceuticals stock or one of its competitors? MarketBeat compares Rocket Pharmaceuticals with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Rocket Pharmaceuticals include Ainos (AIMDW), Alvotech (ALVOW), Aravive (ARAV), Atlantic Coastal Acquisition Corp. II (ACABW), and Biofrontera (BFRIW). These companies are all part of the "pharmaceutical products" industry.

How does Rocket Pharmaceuticals compare to Ainos?

Ainos (NASDAQ:AIMDW) and Rocket Pharmaceuticals (NASDAQ:RCKTW) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, analyst recommendations, earnings, dividends, media sentiment, valuation, profitability and institutional ownership.

Company Net Margins Return on Equity Return on Assets
AinosN/A N/A N/A
Rocket Pharmaceuticals N/A N/A N/A

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Ainos$18.11KN/AN/AN/AN/A
Rocket PharmaceuticalsN/AN/AN/AN/AN/A

In the previous week, Ainos and Ainos both had 2 articles in the media. Ainos' average media sentiment score of 1.43 equaled Rocket Pharmaceuticals'average media sentiment score.

Company Overall Sentiment
Ainos Positive
Rocket Pharmaceuticals Positive

Summary

Ainos beats Rocket Pharmaceuticals on 1 of the 1 factors compared between the two stocks.

How does Rocket Pharmaceuticals compare to Alvotech?

Alvotech (NASDAQ:ALVOW) and Rocket Pharmaceuticals (NASDAQ:RCKTW) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their profitability, earnings, risk, analyst recommendations, institutional ownership, dividends, media sentiment and valuation.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Alvotech$559.42MN/AN/AN/AN/A
Rocket PharmaceuticalsN/AN/AN/AN/AN/A

Company Net Margins Return on Equity Return on Assets
AlvotechN/A N/A N/A
Rocket Pharmaceuticals N/A N/A N/A

In the previous week, Alvotech and Alvotech both had 2 articles in the media. Rocket Pharmaceuticals' average media sentiment score of 1.43 beat Alvotech's score of 0.93 indicating that Rocket Pharmaceuticals is being referred to more favorably in the news media.

Company Overall Sentiment
Alvotech Positive
Rocket Pharmaceuticals Positive

Summary

Alvotech and Rocket Pharmaceuticals tied by winning 1 of the 2 factors compared between the two stocks.

How does Rocket Pharmaceuticals compare to Aravive?

Aravive (NASDAQ:ARAV) and Rocket Pharmaceuticals (NASDAQ:RCKTW) are both medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their risk, earnings, analyst recommendations, institutional ownership, profitability, dividends, media sentiment and valuation.

In the previous week, Rocket Pharmaceuticals had 2 more articles in the media than Aravive. MarketBeat recorded 2 mentions for Rocket Pharmaceuticals and 0 mentions for Aravive. Rocket Pharmaceuticals' average media sentiment score of 1.43 beat Aravive's score of 0.00 indicating that Rocket Pharmaceuticals is being referred to more favorably in the news media.

Company Overall Sentiment
Aravive Neutral
Rocket Pharmaceuticals Positive

Company Net Margins Return on Equity Return on Assets
AraviveN/A N/A N/A
Rocket Pharmaceuticals N/A N/A N/A

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
AraviveN/AN/AN/A-$0.90N/A
Rocket PharmaceuticalsN/AN/AN/AN/AN/A

35.8% of Aravive shares are owned by institutional investors. 60.4% of Aravive shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Summary

Aravive and Rocket Pharmaceuticals tied by winning 2 of the 4 factors compared between the two stocks.

How does Rocket Pharmaceuticals compare to Atlantic Coastal Acquisition Corp. II?

Atlantic Coastal Acquisition Corp. II (NASDAQ:ACABW) and Rocket Pharmaceuticals (NASDAQ:RCKTW) are both pharmaceutical products companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, valuation, profitability, institutional ownership, media sentiment, earnings, risk and analyst recommendations.

In the previous week, Rocket Pharmaceuticals had 2 more articles in the media than Atlantic Coastal Acquisition Corp. II. MarketBeat recorded 2 mentions for Rocket Pharmaceuticals and 0 mentions for Atlantic Coastal Acquisition Corp. II. Rocket Pharmaceuticals' average media sentiment score of 1.43 beat Atlantic Coastal Acquisition Corp. II's score of 0.00 indicating that Rocket Pharmaceuticals is being referred to more favorably in the news media.

Company Overall Sentiment
Atlantic Coastal Acquisition Corp. II Neutral
Rocket Pharmaceuticals Positive

Company Net Margins Return on Equity Return on Assets
Atlantic Coastal Acquisition Corp. IIN/A N/A N/A
Rocket Pharmaceuticals N/A N/A N/A

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Atlantic Coastal Acquisition Corp. IIN/AN/AN/AN/AN/A
Rocket PharmaceuticalsN/AN/AN/AN/AN/A

Summary

Rocket Pharmaceuticals beats Atlantic Coastal Acquisition Corp. II on 2 of the 2 factors compared between the two stocks.

How does Rocket Pharmaceuticals compare to Biofrontera?

Rocket Pharmaceuticals (NASDAQ:RCKTW) and Biofrontera (NASDAQ:BFRIW) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their valuation, profitability, earnings, risk, analyst recommendations, institutional ownership, media sentiment and dividends.

Company Net Margins Return on Equity Return on Assets
Rocket PharmaceuticalsN/A N/A N/A
Biofrontera N/A N/A N/A

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Rocket PharmaceuticalsN/AN/AN/AN/AN/A
Biofrontera$43.20MN/AN/AN/AN/A

In the previous week, Rocket Pharmaceuticals and Rocket Pharmaceuticals both had 2 articles in the media. Biofrontera's average media sentiment score of 1.44 beat Rocket Pharmaceuticals' score of 1.43 indicating that Biofrontera is being referred to more favorably in the news media.

Company Overall Sentiment
Rocket Pharmaceuticals Positive
Biofrontera Positive

Summary

Biofrontera beats Rocket Pharmaceuticals on 2 of the 2 factors compared between the two stocks.

Get Rocket Pharmaceuticals News Delivered to You Automatically

Sign up to receive the latest news and ratings for RCKTW and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

RCKTW vs. The Competition

Export
MetricRocket PharmaceuticalsBiotechnology IndustryMedical SectorNASDAQ Exchange
Market CapN/A$500.33M$6.84B$12.44B
Dividend YieldN/A3.87%2.67%6.11%
P/E RatioN/A3.1725.8324.36
Price / SalesN/A6,785.99540.6096.08
Price / CashN/A13.1329.0936.93
Price / BookN/A89.3710.986.49
Net IncomeN/A-$96.07M$3.57B$336.61M
7 Day PerformanceN/A1.23%3.05%0.91%
1 Month PerformanceN/A-0.19%0.72%-0.35%
1 Year PerformanceN/A74.49%36.81%31.28%

Rocket Pharmaceuticals Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
RCKTW
Rocket Pharmaceuticals
N/A$0.01
-13.0%		N/A-79.0%$0.00N/AN/A240
AIMDW
Ainos
N/A$0.08
-38.5%		N/A-20.5%$0.00$18.11KN/A40
ALVOW
Alvotech
N/A$0.33
flat		N/AN/A$0.00$559.42MN/A4
ARAV
Aravive
N/A$0.04
flat		N/AN/A$0.00N/AN/A20
ACABW
Atlantic Coastal Acquisition Corp. II
N/A$0.00
flat		N/AN/A$0.00N/AN/A15

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:RCKTW) was last updated on 6/29/2026 by MarketBeat.com Staff.
From Our Partners
Trump's gold order: the announcement they won't put on the front page
On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...
Reagan Gold Group | Sponsoredtc pixel
Trump Takes Emergency Action - Plus Elon Musk's New Venture
Elon Musk has quietly launched a new venture - one that has nothing to do with rockets, EVs, or Neuralink. Tru...
Altimetry | Sponsoredtc pixel
Do NOT Buy SpaceX – Do This Instead
SpaceX just went public - and Whitney Tilson, Harvard MBA and 30-year Wall Street veteran, says buying in coul...
Stansberry Research | Sponsoredtc pixel
SpaceX is offering you shares. Don't take them.
SpaceX is reserving 30% of its IPO shares for retail investors through Robinhood, Fidelity, and Schwab. At a $...
Behind the Markets | Sponsoredtc pixel
Trump just signed it
A recent policy development is drawing attention from income-focused investors. According to one analyst, c...
Investors Alley | Sponsoredtc pixel
CODE RED: AI Meltdown Imminent?
After correctly predicting the 2008 and 2020 stock market meltdowns, I believe this AI company is about to tri...
Paradigm Press | Sponsoredtc pixel
Porter flew 3,300 miles to investigate this system
Porter Stansberry flew the Porter and Co. team 3,300 miles to Dublin to investigate a 17-year investing experi...
Porter & Company | Sponsoredtc pixel
Better than SpaceX? Grab this ticker instead.
Larry Benedict generated $274 million for his clients by finding the trades most investors missed. Now he says...
Brownstone Research | Sponsoredtc pixel